<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867423</url>
  </required_header>
  <id_info>
    <org_study_id>2009/01 CYBERBOOST</org_study_id>
    <nct_id>NCT02867423</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiation by CyberKnife as a Mean of the Tumor Site's Radiation After Conventional Breast Radiation.</brief_title>
  <acronym>CYBERBOOST</acronym>
  <official_title>PHASE II STUDY : Hypofractionated Radiation by CyberKnife as a Mean of Radiation of the Tumor Site After Conventional Breast Radiation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CyberKnife (CK) has been developed recently. This is a linear accelerator carried by an&#xD;
      industrial robot. It has, due to its tumor tracking capabilities and high accuracy, an&#xD;
      interest in irradiation (boost) of tumor site after conventional irradiation. The radiation&#xD;
      boost is currently issued by electrons, protons or brachytherapy. These techniques require&#xD;
      several fractions and are associated with cutaneous toxicities and aesthetic problems. CK has&#xD;
      an interest in reducing the number of fractions and a reduction of dose delivered to the&#xD;
      skin.&#xD;
&#xD;
      CK has been used in a phase I protocol (CYBERNEO) with concomitant chemotherapy for&#xD;
      inoperable breast tumors and has proven its effectiveness and safety of treatments.&#xD;
&#xD;
      The investigator is considering conducting a Phase II protocol to a single dose of 8 Grays&#xD;
      issued by CK for boost to the tumor site after conventional breast irradiation.&#xD;
&#xD;
      The results, in terms of local control, will be evaluated on clinical monitoring.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EORTC score for erythema, telangiectasia, edema, pain</measure>
    <time_frame>2 months</time_frame>
    <description>early skin toxicity evaluation by clinical examination (radiation oncology and dermatologist) using EORTC score for erythema, telangiectasia, edema, pain.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A - CK boost radiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CK boost radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CK Boost radiation</intervention_name>
    <description>single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation</description>
    <arm_group_label>A - CK boost radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. unifocal breast cancer histologically proven&#xD;
&#xD;
          2. Age&gt; 18 years old, in good general condition (ECOG 0-2)&#xD;
&#xD;
          3. No cons-indication for radiotherapy&#xD;
&#xD;
          4. Patient who underwent lumpectomy and axillary dissection or sentinel node technique.&#xD;
&#xD;
          5. carcinoma histology ductal or lobular carcinoma&#xD;
&#xD;
          6. surgical margins microscopically without residual disease (&gt; 1 mm)&#xD;
&#xD;
          7. tumors classes T1 or T2, N0&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. residual calcifications on X-ray examination&#xD;
&#xD;
          2. Inflammatory breast cancer, ductal (and / or in situ) and invasive lobular&#xD;
&#xD;
          3. multifocal breast Cancer&#xD;
&#xD;
          4. prior Breast radiotherapy&#xD;
&#xD;
          5. Patient who received chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Yves BONDIAU, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine LACASSAGNE</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

